History & Mission Statement



Oligomerix was founded in 2006 and has focused its research efforts on the role of tau protein in neurodegenerative disease. The Company has advanced its lead program from biochemical assays to in vivo studies and is looking for a pharmaceutical partner to accelerate this program to clinical development.

Mission Statement

The mission of Oligomerix is to discover and develop the most effective disease modifying therapeutics to meet the major global unmet medical need for Alzheimer’s and related neurodegenerative diseases by targeting tau oligomers.